This is an index of side effect / adverse reaction reports (a.k.a. adverse event reports) related to Infergen (Interferon Alfacon-1) and submitted to the FDA during the sample period of about a year. The information is not vetted and should not be considered as verified clinical evidence.
Reports by Event Outcome
All Cases (10)
Reports by Reaction Type
Treatment Failure (4),
Pain (2),
Neoplasm Progression (2),
Multiple Myeloma (2),
Refractory Cytopenia With Multilineage Dysplasia (2),
Influenza Like Illness (2),
Polyneuropathy (2),
Stem Cell Transplant (2),
Fatigue (2),
Obesity (2),
Depression (2),
Thrombocytopenia (2)
Possible Infergen side effects in
Reported by a consumer/non-health professional from United States on 2012-08-23
Patient:
Reactions: Treatment Failure
Drug(s) suspected as cause:
Infergen
Pegasys
Therapy Unspecified
Possible Infergen side effects in
Reported by a consumer/non-health professional from United States on 2012-07-16
Patient:
Reactions: Treatment Failure
Drug(s) suspected as cause:
Infergen
Rebetol
Possible Infergen side effects in 49 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-03
Patient: 49 year old female, weighing 102.1 kg (224.5 pounds)
Reactions: Pain, Pyrexia, Malaise, Fatigue, Skin Ulcer, Medication Error, Depression, Rash Vesicular, Blood Test Abnormal, Staphylococcal Skin Infection, White Blood Cell Count Decreased, Skin Disorder, Impaired Healing, Asthenia, Mobility Decreased, Influenza Like Illness
Drug(s) suspected as cause:
Ribavirin
Dosage: 600 mg, 3 days a week, oral, 600 mg in morning and evening, daily
Administration route: Oral
Indication: Hepatitis C
Start date: 2011-05-01
Ribavirin
Dosage: 600 mg, 3 days a week, oral, 600 mg in morning and evening, daily
Administration route: Oral
Indication: Hepatitis C
Start date: 2011-11-08
Infergen
Dosage: treated for wrong genotype 1, 15 mcg/0.5ml, thrice weekly, injection, subcutaneous
Indication: Hepatitis C
Start date: 2011-05-01
Infergen
Dosage: treated for wrong genotype 1, 15 mcg/0.5ml, thrice weekly, injection, subcutaneous
Indication: Hepatitis C
Start date: 2011-11-08
Other drugs received by patient: Fosamax; Clonazepam; Isoniazid; Bactroban; Topamax; Hibiclens; Oxygen; Prednisone TAB; Calcium / Vitamin D; Methadone HCL; Phenergan HCL; Triamcinolone Acetonide; Motrin; Xanax; Clindamycin Phosphate; Dulera Oral Inhalation; Ventolin
Possible Infergen side effects in 61 year old male
Reported by a physician from United States on 2012-03-21
Patient: 61 year old male
Reactions: Anaemia, Obesity, Treatment Failure, Thrombocytopenia, Polyneuropathy
Drug(s) suspected as cause:
PEG-Intron
Indication: Hepatitis C
Infergen
Indication: Hepatitis C
Start date: 2008-01-01
Ribavirin
Indication: Hepatitis C
Possible Infergen side effects in 49 year old male
Reported by a health professional (non-physician/pharmacist) from Greece on 2011-12-02
Patient: 49 year old male
Reactions: Stem Cell Transplant, Neoplasm Progression, Multiple Myeloma, Refractory Cytopenia With Multilineage Dysplasia
Drug(s) suspected as cause:
Cisplatin
Indication: Multiple Myeloma
Melphalan Hydrochloride
Dosage: 10 cycles
Indication: Multiple Myeloma
Cytarabine
Indication: Multiple Myeloma
Start date: 1998-11-01
Ifosfamide
Indication: Multiple Myeloma
Carmustine
Indication: Multiple Myeloma
Start date: 1998-11-01
Etoposide
Indication: Multiple Myeloma
Cyclophosphamide
Indication: Multiple Myeloma
Infergen
Dosage: 3 x 10 iu thrice weekly
Indication: Multiple Myeloma
End date: 2005-09-01
Prednisone TAB
Indication: Multiple Myeloma
Dexamethasone
Indication: Multiple Myeloma
Possible Infergen side effects in 55 year old male
Reported by a physician from United States on 2011-11-25
Patient: 55 year old male, weighing 113.4 kg (249.5 pounds)
Reactions: Listless, Nausea, Chills, Pain of Skin, Bone Pain, Pain, Hyperhidrosis, Feeling Cold, Tremor, Myalgia, Fatigue, Decreased Appetite
Drug(s) suspected as cause:
Infergen
Dosage: 15 microgram once a day, subcutaneous
Indication: Hepatitis C
Start date: 2010-04-21
Ribavirin
Dosage: 600 mg twice daily, oral
Administration route: Oral
Indication: Hepatitis C
Start date: 2010-04-21
Possible Infergen side effects in 49 year old male
Reported by a health professional (non-physician/pharmacist) from Greece on 2011-11-23
Patient: 49 year old male
Reactions: Stem Cell Transplant, Neoplasm Progression, Refractory Cytopenia With Multilineage Dysplasia, Multiple Myeloma
Drug(s) suspected as cause:
Dexamethasone
Indication: Multiple Myeloma
Prednisone TAB
Indication: Multiple Myeloma
Infergen
Dosage: 3 x 10 iu thrice weekly
Indication: Multiple Myeloma
Etoposide
Indication: Multiple Myeloma
Cyclophosphamide
Indication: Multiple Myeloma
Cytarabine
Indication: Multiple Myeloma
Start date: 1998-11-01
Carmustine
Indication: Multiple Myeloma
Start date: 1998-11-01
Ifosfamide
Indication: Multiple Myeloma
Cisplatin
Indication: Multiple Myeloma
Melphalan Hydrochloride
Dosage: 10 cycles
Indication: Multiple Myeloma
Possible Infergen side effects in 61 year old male
Reported by a physician from United States on 2011-11-02
Patient: 61 year old male
Reactions: Anaemia, Obesity, Treatment Failure, Thrombocytopenia, Polyneuropathy
Drug(s) suspected as cause:
Ribavirin
Indication: Hepatitis C
End date: 2008-01-01
PEG-Intron
Indication: Hepatitis C
Infergen
Indication: Hepatitis C
End date: 2008-01-01
Possible Infergen side effects in 58 year old male
Reported by a consumer/non-health professional from United States on 2011-10-19
Patient: 58 year old male
Reactions: Weight Increased, Muscle Atrophy, Depression
Drug(s) suspected as cause:
Ribavirin
Indication: Product Used FOR Unknown Indication
Infergen
Indication: Product Used FOR Unknown Indication
Possible Infergen side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-04
Patient: female
Reactions: Dysarthria, Concussion, Fall, Amnesia, Loss of Consciousness, Influenza Like Illness
Drug(s) suspected as cause:
Ribavirin
Indication: Hepatitis C
Start date: 2009-01-01
End date: 2009-11-01
Infergen
Indication: Hepatitis C
Start date: 2009-01-01
End date: 2009-11-01
|